Prior to joining QRxPharma, Mr Soriano was senior director of business development at Osiris Therapeutics and responsible for all business development activities, including IP strategy and operations, out-licensing and divestiture.
John Holaday, managing director and CEO of QRxPharma, said: “We are very pleased to announce that Dr Soriano has joined our senior management team. Our approach has been to build a team of people who add value, broaden our collective knowledge and bring the experience necessary to advance the company’s goals. I am confident Dr Soriano will contribute significantly to QRxPharma’s success.”